Home / Catalogue/ Metabolic/ Cagrilintide

MetabolicIn StockSubQ injection

Cagrilintide

Acylated peptide · Long-acting amylin analogue · Synthetic

Half-life

~7d

After administration

Delivery Method

SubQ injection

Route of administration

Storage (Lyophilised)

12-24 months

2–8°C

Storage (Reconstituted)

4–6 weeks

Refrigerate at 2-8C

Known For

Long-acting amylin analogue. Reduces appetite through a different pathway than GLP-1 agonists. Being developed as part of CagriSema (cagrilintide + semaglutide) which showed ~25% weight loss in trials.

Mechanism of Action

Long-acting amylin analog — mimics pancreatic hormone that reduces appetite and slows gastric emptying via brainstem satiety centres

Body vs. External Supply

🔴 Exogenous (replaces natural)

Brand / Trade Names

No brand name yet (Investigational — Novo Nordisk) Studied as part of CagriSema

Typical Research Dosage

0.5mg → 1mg → 2mg → 4mg weekly SubQ. Titrate every 4 weeks.

Vial Duration Guide

5mg vial at 1mg/wk = 5 weeks. At 2.4mg/wk = ~2 weeks.

Recommended Vial Size

★ 5mg vials At 1-2mg/wk, 5mg lasts 2.5-5 weeks ✓. 10mg risks exceeding shelf life at lower titration doses.

Time to Effects

EARLY: 2-4 weeks FULL: 16-24 weeks As a standalone (without semaglutide), appetite suppression noticeable within 2-4 weeks. Weight loss is more modest than GLP-1 agonists alone. The real value is in the CagriSema combination. Standalone cagrilintide showed ~10-11% weight loss at 32 weeks in trials. Minimum commitment: 12 weeks.

Contraindications & Do Not Combine

• Do NOT combine with other amylin analogues • CAN combine with Semaglutide (this is CagriSema — the intended pairing) • Do NOT combine with Tirzepatide or Retatrutide alongside CagriSema

Common Side Effects

Nausea (18-25%), injection site reactions (6%), diarrhoea, headache

Drug Interactions

Insulin (may ↑hypoglycaemia). May slow absorption of oral meds. Avoid with pramlintide.

Reversibility

Limited data. Weight regain expected off treatment.

Key Peer-Reviewed References

All studies are published in indexed journals unless otherwise noted.

• Lau DCW et al. (2021) Phase 2. Lancet 397:2486-96. DOI: 10.1016/S0140-6736(21)00845-X • Studied as standalone and in combination with semaglutide (CagriSema) • NOT YET FDA APPROVED

Research Disclaimer

Almost all data is preclinical (animal or in-vitro). No large-scale randomised controlled human trials are available for most compounds on this catalogue. This information is provided for research reference only.

Storage Requirements

2-8°C

State	Condition	Duration
Lyophilised (sealed)	2–8°C	12-24 months
Reconstituted	2-8C	4–6 weeks

Reconstitution Note

Reconstitute with bacteriostatic water (BAC water). Do not shake vigorously -- swirl gently to dissolve. Inject BAC water slowly down the side of the vial to avoid denaturing the peptide.

Video Resources

Cagrilintide discussed by researchers & practitioners

Independent educational content from researchers, clinicians, and science communicators. Not affiliated with Pepnerd — provided as supplementary reading.

Educational resources only. The videos above are independent third-party content from researchers, clinicians, and science communicators. Pepnerd is not affiliated with any of these creators and does not endorse or make any claims based on their content. All products are sold strictly for in-vitro scientific research.

Select Vial Size

$130.00 per vial

Submit Your Test Results →

Quick Reference

Half-life	~7 days (long-acting amylin analog)
Delivery	SubQ injection
Typical dose	0.5mg
Storage (lyoph.)	2–8°C
Storage (recon.)	4–6 weeks
Endogenous?	Exogenous (replaces natural)
Suppression	None known
WADA	Not listed — investigational
FDA status	Phase 3 trials